Results 151 to 160 of about 30,886 (233)

Multiple cell-type interactions drive invariant NKT cell hepatitis. [PDF]

Hepatol Commun
Tan J, Ji L, Li Q, Guo R, Hao Y, Xiao P, Zai Q, Zhang X, Gao Y, Zhang X, Fang M, Gao Y, Zhao W, He Y, Gao Y, Li M.   +15 more
europepmc   +1 more source

Use of a Clostridioides difficile Murine Immunization and Challenge Model to Evaluate Single and Combination Vaccine Adjuvants Consisting of Alum and NKT Cell-Activating Ligands. [PDF]

Front Immunol, 2021
Lang GA, Norman K, Amadou Amani S, Shadid TM, Ballard JD, Lang ML.   +5 more
europepmc   +1 more source

TCF/LEF family transcription factors: Molecular landscape and prognostic scoring in pan‐cancer

Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.
This study provides a comprehensive molecular landscape of TCF/LEF family transcription factors across 33 cancer types. We developed a TCF/LEF‐based prognostic score that correlates with immune infiltration, metabolic reprogramming and drug sensitivity, offering a robust transcriptomic signature for predicting patient survival and therapeutic response.
Zhengjun Yang, D. Q. Cai, Zhen Zhao, Zhixiang Jian, Mude Shi, Yajin Chen, Jueming Chen, Chunhua Qu, Diankui Cai   +8 more
wiley   +1 more source

The α glycolipid rules the NKT cell TCR. [PDF]

J Exp Med
Kronenberg M, Ascui G.
europepmc   +1 more source

Unexpected Pro-Fibrotic Effect of MIF in Non-Alcoholic Steatohepatitis Is Linked to a Shift in NKT Cell Populations. [PDF]

Cells, 2021
Heinrichs D, Brandt EF, Fischer P, Köhncke J, Wirtz TH, Guldiken N, Djudjaj S, Boor P, Kroy D, Weiskirchen R, Bucala R, Wasmuth HE, Strnad P, Trautwein C, Bernhagen J, Berres ML.   +15 more
europepmc   +1 more source

The Dual Role of the Gut Microbiota in Cancer Chemoresistance

MicrobiologyOpen, Volume 15, Issue 4, August 2026.
Comparison between Microbiota and Cancer therapy. ABSTRACT Chemoresistance is one of the primary reasons that cancer chemotherapy fails to deliver successful treatment outcomes and contributes to poor overall survival rates for patients with cancer. New research has begun to shed light on the effects of the gut microbiome (GM).
Hamed Tahmasebi, Aisa Bahar, Meisam Khazaei, Mohammad Reza Arabestani   +3 more
wiley   +1 more source

Differential Immune Checkpoint Expression in CD4⁺ and CD4^- NKT Cell Populations During Healthy Pregnancy. [PDF]

Int J Mol Sci
Meggyes M, David NU, Mezosi L, Vastag F, Kevey D, Szereday L.   +5 more
europepmc   +1 more source

Turning Cold Tumors Into Hot Tumors: Implications for Cancer Therapy

MedComm, Volume 7, Issue 8, August 2026.
Barrier‐defined strategies for cold‐to‐hot tumor conversion. Cold tumors include immune‐desert and immune‐excluded states marked by poor antigen visibility, limited T‐cell priming, stromal or vascular exclusion, metabolic stress and suppressive immune programs.
Xiao Ge, Dong Han, Jing Wang, Xinyu Dai, Chen Ma, Feihong Chen   +5 more
wiley   +1 more source

Patient-Derived Organoid Models for NKT Cell-Based Cancer Immunotherapy. [PDF]

Cancers (Basel)
Palacios PA, Flores I, Cereceda L, Otero FF, Müller M, Brebi P, Contreras HR, Carreño LJ.   +7 more
europepmc   +1 more source

CCL20 Released by Drug–Tolerant Persisters Impairs Immunotherapy in EGFR–Mutant Lung Adenocarcinoma

MedComm, Volume 7, Issue 8, August 2026.
Schematic representation of tumor immune microenvironment (TIME) modulation by combined anti‐PD‐1 and anti‐CCL20 therapies. Left: In the “cold” tumor TIME, high CCL20 secretion by drug‐tolerant persister (DTP) cancer cell subpopulations promotes regulatory T cell (Treg) enrichment and clusters in close proximity to tumor cells, resulting in immune ...
Hoi‐Hin Kwok, Jiashuang Yang, Nerissa Chui‐Mei Lee, Junyang Deng, David Chi‐Leung Lam   +4 more
wiley   +1 more source